🇺🇸 Low-dose cytarabine (LDAC) in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 8

Most-reported reactions

1. Acute Myeloid Leukaemia Recurrent — 1 report (12.5%)
2. Death — 1 report (12.5%)
3. Enterococcal Bacteraemia — 1 report (12.5%)
4. Escherichia Bacteraemia — 1 report (12.5%)
5. Febrile Neutropenia — 1 report (12.5%)
6. Neutropenia — 1 report (12.5%)
7. Off Label Use — 1 report (12.5%)
8. Thrombocytopenia — 1 report (12.5%)

Source database →

Frequently asked questions

Is Low-dose cytarabine (LDAC) approved in United States?

Low-dose cytarabine (LDAC) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Low-dose cytarabine (LDAC) in United States?

Celgene is the originator. The local marketing authorisation holder may differ — check the official source linked above.